References
1. World Health Organization. Global progress report on HIV,
viral hepatitis and sexually transmitted infections, 2021:
accountability for the global health sector strategies 2016–
2021: actions for impact.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA,
Jemal A. GLOBOCAN estimates of incidence and mortality
worldwide for 36 cancers in 185 countries. Ca Cancer J Clin.
2018 Nov;68(6):394-424.
3. Salarnia F, Behboudi E, Shahramian I, Moradi A. Novel X
gene point mutations in chronic hepatitis B and HBV related
cirrhotic patients. Infection, Genetics and Evolution. 2022;
97:105186.
4. Dolati F, Behboudi E, Naderi M, Shahramian I, Moradi A.
Evaluation of Lamivudine Resistance Mutations in HBV/HIV
Co-infected Patients. Iranian Journal of Medical
Microbiology. 2022;16(1):66-75.
5. WEI Z, SHEN X, NI B, LUO G, TIAN Y, SUN Y.
Contribution of hepatitis B virus X protein-induced aberrant
microRNA expression to hepatocellular carcinoma
pathogenesis. TURKISH J Biol. 2019; 43(2):113-23.
6. Khattar E, Mukherji A, Kumar V. Akt augments the
oncogenic potential of the HBx protein of hepatitis B virus by
phosphorylation. FEBS J. 2012; 279(7):1220-30.
7. Wu CS, Yen CJ, Chou RH, Chen JN, Huang WC, Wu CY, et
al. Downregulation of microRNA-15b by hepatitis B virus X
enhances hepatocellular carcinoma proliferation via
fucosyltransferase 2-induced Globo H expression. Int J
Cancer. 2014; 134(7):1638-47.
8. Zhang T, Zhang J, Cui M, Liu F, You X, Du Y, et al.
Hepatitis B virus X protein inhibits tumor suppressor miR-205
through inducing hypermethylation of miR-205 promoter to
enhance carcinogenesis. Neoplasia (United States). 2013;
15(11):1282-IN26
9. Mohebbi A, Shakeri-Moghaddam A, Doudazndegan Y,
Lorestani N, Mir-Arab A, Moradi A V, et al. Hepatitis B virus
x protein coding sequence variation in chronically infected
patient. J Gorgan Univ Med Sci. 2017;19(3).
10. Mohebbi A, Ebrahimzadeh MS, Rahimi SB, Saeidi M,
Tabarraei A, Mohebbi SR, et al. Non-replicating Newcastle
Disease Virus as an adjuvant for DNA vaccine enhances
antitumor efficacy through the Induction of TRAIL and
granzyme B expression. Virus Res. 2018; 261:72-80.
11. Nakabayashi H, Miyano K, Sato J, Yamane T, Taketa K.
Growth of human hepatoma cell lines with differentiated
functions in chemically defined medium. Cancer Res. 1982;
42(9):3858-63.
12. Gao Y, Feng J, Yang G, Zhang S, Liu Y, Bu Y, et al.
Hepatitis B virus X protein–elevated MSL2 modulates
hepatitis B virus covalently closed circular DNA by inducing
degradation of APOBEC3B to enhance hepatocarcinogenesis.
Hepatology. 2017; 66(5):1413-29.
13. Loukachov V, van Dort KA, Jansen L, Reesink HW,
Kootstra NA. Identification of a novel HBV encoded miRNA
using next generation sequencing. Viruses. 2022;14(6):1223.
14. Yin D, Wang Y, Sai W, Zhang L, Miao Y, Cao L, Zhai X,
Feng X, Yang L. HBx-induced miR-21 suppresses cell
apoptosis in hepatocellular carcinoma by targeting interleukin12. Oncology reports. 2016;36(4):2305-12.
15. Cote GA, Gore AJ, McElyea SD, Heathers LE, Xu H,
Sherman S and Korc M: A pilot study to develop a diagnostic
test for pancreatic ductal adenocarcinoma based on differential
expression of select miRNA in plasma and bile. Am J
Gastroenterol. 109:1942–1952. 2014;
16. Holotnakova T, Tylkova L, Takacova M, Kopacek J, Petrik
J, Pastorekova S, et al. Role of the HBx oncoprotein in
carbonic anhydrase 9 induction. J Med Virol. 2010; 82(1):32-
40.
17. Zhang B, Han S, Feng B, Chu X, Chen L, Wang R. Hepatitis
B virus X protein-mediated non-coding RNA aberrations in
the development of human hepatocellular carcinoma.
Experimental and Molecular Medicine. 2017: 49(2):e293-.
18. Catana CS, Pichler M, Giannelli G, Mader RM, BerindanNeagoe I. Non-coding RNAs, the Trojan horse in two-way
communication between tumor and stroma in colorectal and
hepatocellular carcinoma. Oncotarget. 2017; 8(17):29519.
19. Felekkis K, Touvana E, Stefanou C, Deltas C. MicroRNAs:
A newly described class of encoded molecules that play a role
in health and disease. Hippokratia. 2010; 14(4):236.
20. Ling H, Fabbri M, Calin GA. MicroRNAs and other noncoding RNAs as targets for anticancer drug development.
Nature Reviews Drug Discovery. 2013; 12(11):847-65.
21. Zhang X, Tang W, Li R, He R, Gan T, Luo Y, Chen G,
Rong M. Downregulation of microRNA-132 indicates
progression in hepatocellular carcinoma. Experimental and
Therapeutic Medicine. 2016;12(4):2095-101.
Khosravi et al / Archives of Razi Institute, Vol. 79, No. 1 (2024) 118-125 125
22. Dhanasekaran R, Bandoh S, Roberts LR. Molecular
pathogenesis of hepatocellular carcinoma and impact of
therapeutic advances [version 1; referees: 4 approved].
F1000Research. 2016;5.
23. Keshavarz M, Miri SM, Behboudi E, Arjeini Y, DianatMoghadam H, Ghaemi A. Oncolytic virus delivery modulated
immune responses toward cancer therapy: Challenges and
perspectives. International Immunopharmacology.
2022;108:108882.
24. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A,
Petrocca F, et al. A microRNA expression signature of human
solid tumors defines cancer gene targets. Proc Natl Acad Sci U
S A. 2006; 103(7):2257-61.
25. Wei X, Tan C, Tang C, Ren G, Xiang T, Qiu Z, et al.
Epigenetic repression of miR-132 expression by the hepatitis
B virus x protein in hepatitis B virus-related hepatocellular
carcinoma. Cell Signal. 2013; 25(5):1037-43.
26. Roy G, Roy P. MicroRNAs in hepatocellular
carcinoma – therapeutics and beyond: A systematic review. IJS
Short Reports. 2017; 2(2):10-6.
27. Arataki K, Hayes CN, Akamatsu S, Akiyama R, Abe H,
Tsuge M, et al. Circulating microRNA-22 correlates with
microRNA-122 and represents viral replication and liver
injury in patients with chronic hepatitis B. J Med Virol. 2013;
85(5):789-98.
28. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV,
Ciafrè SA, et al. miR-221 and miR-222 expression affects the
proliferation potential of human prostate carcinoma cell lines
by targeting p27 Kip1. J Biol Chem 2007;282(32):23716–24.
29. Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM,
Brackett DJ, et al. Association of microRNA expression in
hepatocellular carcinomas with hepatitis infection, cirrhosis,
and patient survival. Clin Cancer Res. 2008; 14(2):419-27.
30. Le Sage C, Nagel R, Egan DA, Schrier M, Mesman E,
Mangiola A, et al. Regulation of the p27Kip1 tumor
suppressor by miR-221 and miR-222 promotes cancer cell
proliferation. EMBO J. 2007; 26(15):3699-708
)